SCHEMBL3761931

SCHEMBL3761931

Cc1ccc[c]c1NCc1ccco1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
MAPT P10636 5/20 0.45
KDM4E B2RXH2 5/20 0.45
GAA P10253 4/20 0.45
TDP1 Q9NUW8 1/20 0.45
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HSD17B10 Q99714 2/20 0.42
PKM P14618 1/20 0.42
LMNA P02545 3/20 0.41
HTT P42858 2/20 0.41
MAPK1 P28482 2/20 0.41
BLM P54132 1/20 0.41
POLB P06746 2/20 0.41
TSHR P16473 1/20 0.40
TP53 P04637 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11332749 0.75 ALDH1A1 (0.51) ALDH1A1MAPTKDM4EGAATDP1
SCHEMBL3769314 0.72 KMT2A (0.47) ALDH1A1MAPTKDM4EGAASMN1; SMN2
SCHEMBL11650552 0.72 MAPT (0.34) MAPTHTTTSHR
SCHEMBL28689647 0.70 KMT2A (0.51) ALDH1A1MAPTKDM4EGAASMN1; SMN2
SCHEMBL15455447 0.68 ALDH1A1 (0.54) ALDH1A1MAPTKDM4EGAATDP1
SCHEMBL11792458 0.68 SMN1; SMN2 (0.59) ALDH1A1MAPTKDM4EGAATDP1
SCHEMBL11655942 0.67 ALDH1A1 (0.33) ALDH1A1MAPTKDM4EGAASMN1; SMN2
SCHEMBL172653 0.66
SCHEMBL2805209 0.65 ALDH1A1 (0.68) ALDH1A1MAPTKDM4EGAATDP1
SCHEMBL843371 0.65 CHRM2 (0.69) ALDH1A1GAATDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA ALDH1A1 3061/4885MAPT 790/4885KDM4E 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.